Table 1.
Baseline patient characteristics, stratified by disease duration (defined from 1st non-Raynaud sign or symptom)
| Variables | All Patients (N=77) | Group A (N=22) Disease dur 0–2 years |
Group B (N=33) Disease dur 2–4 years |
Group C (N=22) Disease dur >4 years |
|---|---|---|---|---|
| Age, years, Mean (SD)* | 48.3 (12.5) | 56.2 (12.4) | 46.4 (11.9) | 43.4 (10.1) |
| Female, N (%) | 48.0 (62.3) | 12.0 (54.6) | 18.0 (54.6) | 18.0 (81.8) |
| Race, N (%) | ||||
| White | 51.0 (66.2) | 15.0 (68.2) | 22.0 (66.7) | 14.0 (63.6) |
| Type of SSc, N (%) | ||||
| Limited | 32 (41.6) | 8.0 (36.4) | 16.0 (48.5) | 8.0 (36.4) |
| Diffuse | 45.0 (58.4) | 14.0 (63.6) | 17.0 (51.5) | 14.0 (63.6) |
| Disease duration, yrs, Mean (SD)* | 3.2 (1.9) | 1.1 (0.6) | 3.0 (0.6) | 5.7 (0.7) |
| Antibodies (N=55), N (%)* | ||||
| SCL-70 | 19 (35) | 1(8) | 7(28) | 11(65) |
| anti-RNA Polymerase III/anti-centromere | 5 (9) | 0(0) | 4(16) | 1(6) |
| Others | 31(56) | 12(92) | 14(56) | 5(29) |
| FVC, %predicted, Mean (SD) | 68.19 (12.9) | 65.5 (13.4) | 68.2 (13.9) | 70.8 (10.7) |
| DLco, %predicted, Mean (SD) | 46.8 (13.9) | 44.9 (13.9) | 46.1 (12.9) | 49.8 (15.6) |
| MRSS, Mean (SD) | 14.2 (10.8) | 16.8 (12.1) | 13.3 (10.5) | 12.9 (9.1) |
| Mahler’s BDI focal score (0–12), Mean(SD)* | 5.7 (1.9) | 6.8 (2.1) | 5.2 (1.8) | 5.4 (1.8) |
| HAQ-DI (0–3), Mean (SD) | 0.70 (0.70) | 0.9 (0.7) | 0.7 (0.7) | 0.6 (0.6) |
| SF-36 PCS (0-00), Mean (SD) | 34.5 (10.8) | 30.4 (11.9) | 35.5 (9.8) | 37.0 (10.5) |
| SF-36 MCS (0-00), Mean (SD) | 50.8 (10.5) | 48.3 (10.7) | 52.9 (8.5) | 50.2 (12.9) |
| HRCT disease extent, Mean (SD) | ||||
| Max Fibrosis Score (0–4) | 2.0 (1.1) | 2.1 (1.2) | 2.0 (1.0) | 2.0 (1.0) |
| Max Honeycombing (0–4) | 0.5 (0.5) | 0.5 (0.5) | 0.5 (0.6) | 0.4 (0.5) |
| Max Ground Glass Opacity (0–4) | 0.7 (0.8) | 0.6 (0.7) | 0.8 (0.9) | 0.7 (0.6) |
*
p< 0.05